Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

By sjmartinez • January 12, 2024

Shah A, Jones MP, Callaghan G, Fairlie T, Ma X, Culver EL, Stuart K, De Cruz P, O'Beirne J, Tabibian JH, Dignass A, Canbay A, Gores GJ, Holtmann GJ. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis. Hepatol Commun. 2024 Jan 11;8(1):e0347. doi: 10.1097/HC9.0000000000000347. PMID: 38206197.

Tags: Digestive Diseases, Olive View DoM, Publications

Distinct risk groups with different healthcare barriers and acute care use exist in the U.S. population with chronic liver disease

Wong CR, Crespi CM, Glenn B, Han SB, Macinko JA, Bastani R. Distinct risk groups with different healthcare barriers and acute care use exist in[...]

Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?

Gukovskaya AS, Lerch MM, Mayerle J, Sendler M, Ji B, Saluja AK, Gorelick FS, Gukovsky I. Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?[...]

Stricturing Crohn’s Disease: When Biologics May Help or Not?

Fansiwala K, Limketkai BN. Stricturing Crohn's Disease: When Biologics May Help or Not? Inflamm Bowel Dis. 2024 Nov 12:izae264. doi: 10.1093/ibd/izae264. Epub ahead of print.[...]